A positive tau PET is more specific than a positive Aβ plaque for diagnosing AD; cognitively typical patients who have positive Aβ plaques and tau PETs are 20x and 40x more likely to develop mild cognitive impairment (MCI) and dementia, respectively. This evidence concerns the gene MAPT and Cognitive impairment.